Feeds

IPO: Patent laws must change to attract Big Pharma to UK

Stringent testing rules strangle drug development, say companies

Beginner's guide to SSL certificates

The government is likely to change patent laws because some pharmaceutical companies are at risk of breaking patent law when carrying out clinical testing, the Intellectual Property Office (IPO) has said.

The IPO said that three-quarters of respondents to its recent consultation on patent infringement in pharmaceutical clinical and field trials had backed changes to the UK's Patents Act. Companies in the pharmaceuticals industry had said that the threat of legal action was stifling the development of innovative new drugs.

"The government acknowledges that the current wording of UK patent legislation does put some parties at risk of patent infringement when preparing and running UK clinical or field trials involving innovative drugs," the IPO said in publishing the results of its consultation. (16-page/480KB PDF)

"From the empirical evidence received, it is apparent that current legislation results in a cost burden to some stakeholders. The scale of these costs varies depending on the patent landscape that surrounds the drug/s used in a trial. However, it is clear that amending the legislation to remove risk of patent infringement would result in a cost saving to those companies who are considering using the UK for clinical trials with innovative drugs," it said.

In 2005 changes were made to the Patents Act to make the use of patented material during some clinical testing of human and animal medicines exempt from being an infringement of patent owners' rights. This is called the 'Bolar exemption' and stems from EU law. Under the Patents Act any act "done for experimental purposes" relating to the subject-matter of an invention are also exempt from being classed as acts of infringement.

The IPO said that research had shown that the UK had become a less popular place for clinical trials to take place. It said that pursuing changes to EU law to clarify the scope of the Bolar exemption would be "slow" and that industry agreements would offer "unacceptable" solutions to the problem.

"Proposing legislative change at the EU level may not receive support from EU Member States whose domestic legislation already deals with this matter," the IPO said. "Industry agreements are considered unacceptable as they may lead to an uncertain infringement situation."

“Although the so called 'Bolar exemption' to patent infringement derives from EU law, member states have implemented it differently in national laws. This has created practical differences and uncertainty from country to country in relation to what acts are considered to be non-infringing,” Camilla Balleny, expert in life sciences at Pinsent Masons, the law firm behind Out-Law.com, said.

“Organisations from across the pharmaceutical industry – including those represented by both the Association of the British Pharmaceutical Industry and those Represented by the European Generics Association - responded to the consultation. The vast majority of respondents have called on changes to be made to UK law to provide further certainty, particularly in relation to clinical trials," Balleny said.

"In October 2005 the UK implemented the Bolar exemption in the same terms as the European Directive. The IPO also issued further guidance on what activities the exemption would cover but there has, despite this, been uncertainty and it is this which the industry has now seemingly confirmed it wants to be clarified by further amendments to the UK law,” Balleny said.

Copyright © 2011, OUT-LAW.com

OUT-LAW.COM is part of international law firm Pinsent Masons.

Choosing a cloud hosting partner with confidence

More from The Register

next story
The 'fun-nification' of computer education – good idea?
Compulsory code schools, luvvies love it, but what about Maths and Physics?
Facebook, Apple: LADIES! Why not FREEZE your EGGS? It's on the company!
No biological clockwatching when you work in Silicon Valley
Happiness economics is bollocks. Oh, UK.gov just adopted it? Er ...
Opportunity doesn't knock; it costs us instead
Ex-US Navy fighter pilot MIT prof: Drones beat humans - I should know
'Missy' Cummings on UAVs, smartcars and dying from boredom
Yes, yes, Steve Jobs. Look what I'VE done for you lately – Tim Cook
New iPhone biz baron points to Apple's (his) greatest successes
Lords take revenge on REVENGE PORN publishers
Jilted Johns and Jennies with busy fingers face two years inside
Sysadmin with EBOLA? Gartner's issued advice to debug your biz
Start hoarding cleaning supplies, analyst firm says, and assume your team will scatter
Edward who? GCHQ boss dodges Snowden topic during last speech
UK spies would rather 'walk' than do 'mass surveillance'
Doctor Who's Flatline: Cool monsters, yes, but utterly limp subplots
We know what the Doctor does, stop going on about it already
prev story

Whitepapers

Forging a new future with identity relationship management
Learn about ForgeRock's next generation IRM platform and how it is designed to empower CEOS's and enterprises to engage with consumers.
Why and how to choose the right cloud vendor
The benefits of cloud-based storage in your processes. Eliminate onsite, disk-based backup and archiving in favor of cloud-based data protection.
Three 1TB solid state scorchers up for grabs
Big SSDs can be expensive but think big and think free because you could be the lucky winner of one of three 1TB Samsung SSD 840 EVO drives that we’re giving away worth over £300 apiece.
Reg Reader Research: SaaS based Email and Office Productivity Tools
Read this Reg reader report which provides advice and guidance for SMBs towards the use of SaaS based email and Office productivity tools.
Security for virtualized datacentres
Legacy security solutions are inefficient due to the architectural differences between physical and virtual environments.